NKX2-4

Across TCGA pan-cancer cohorts, NKX2-4 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated NKX2-4 data layer compared with 17 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher NKX2-4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NKX2-4 expression acts as an unfavorable survival marker.

SKCM, LUSC, and LUAD are the cancer types where NKX2-4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	All	0.233	0.787	.003	15	view →
LUSC	OS	Median	III,IV	0.147	0.664	.028	12	view →
LUAD	DFS	Median	All	0.304	0.792	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

NKX2-4–SKCM (OS)

Open the SKCM breakdown →